Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.94Last Year’s EPS
-0.64Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 0.52%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a balanced outlook, with significant pipeline advancements and strategic focus on mRNA therapeutics leading to an extended cash runway and reduced expenses. However, the revenue decline and net loss present financial challenges. The EU approval of the KOSTAIVE vaccine is a notable achievement, despite conservative expectations for U.S. milestones.Company Guidance
During the first quarter of 2025 earnings call, Arcturus Therapeutics provided guidance on several metrics across its pipeline and financial status. The company emphasized its mRNA therapeutics pipeline, specifically focusing on ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency. ARCT-032 is in an open-label Phase 2 study, with completion of enrollment expected by year-end and interim data for the first two cohorts anticipated by mid-2025. For ARCT-810, interim Phase 2 data is expected in Q2 2025, with biomarkers like glutamine and a 15N ureagenesis assay being utilized. Financially, Arcturus reported Q1 2025 revenue of $29.4 million, a decrease from $38 million in the same period of 2024, and a net loss of $14.1 million. The company extended its cash runway to Q1 2028 by focusing R&D expenditures on CF and OTC programs. It also highlighted EU approval of the KOSTAIVE COVID-19 vaccine and anticipated filings in the UK and US later in 2025, with no immediate milestone payments expected from these approvals.Pipeline Advancements
Arcturus Therapeutics is progressing with its mRNA therapeutics pipeline, including ARCT-032 for cystic fibrosis and ARCT-810 for OTC deficiency, with ongoing Phase 2 studies showing no safety or tolerability issues.
Strategic Focus and Financial Stability
The company has strategically decided to focus resources on mRNA therapeutics, extending its cash runway until the first quarter of 2028 despite a challenging market environment.
EU Approval of KOSTAIVE Vaccine
Arcturus received EU approval for its self-amplifying mRNA COVID-19 vaccine, KOSTAIVE, and an initial milestone payment from CSL.
FDA Fast Track Designation
The company received FDA Fast Track designation for ARCT-2304, its sa-mRNA vaccine candidate for Pandemic Influenza A (H5N1).
Reduction in Operating Expenses
Research and development expenses decreased by $18.7 million year-over-year, and general and administrative expenses decreased by $3.6 million year-over-year.
---
ARCT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ARCT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $11.59 | $11.86 | +2.33% |
Mar 06, 2025 | $15.97 | $14.55 | -8.89% |
Nov 07, 2024 | $18.74 | $19.62 | +4.70% |
Aug 05, 2024 | $19.79 | $19.83 | +0.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Arcturus Therapeutics (ARCT) report earnings?
Arcturus Therapeutics (ARCT) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Arcturus Therapeutics (ARCT) earnings time?
Arcturus Therapeutics (ARCT) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARCT EPS forecast?
ARCT EPS forecast for the fiscal quarter 2025 (Q2) is -0.94.
---
